Abstract
Background Transcranial electrical stimulation has broad potential as a treatment for depression. Transcranial random noise stimulation (tRNS), which delivers randomly fluctuating current intensities, may have greater cortical excitatory effects compared to other forms of transcranial electrical stimulation. We therefore aimed to investigate the antidepressant efficacy of tRNS.
Methods Depressed participants were randomly assigned by computer number generator to receive 20 sessions of either active or sham tRNS over four weeks in a double-blinded, parallel group randomized-controlled trial. tRNS was delivered for 30mins with a direct current offset of 2mA and a random noise range of 2mA. Primary analyses assessed changes in depression severity using the Montgomery-Asperg Depression Rating Scale (MADRS). Neuroplasticity, neuropsychological, and safety outcomes were analysed as secondary measures.
Results 69 participants were randomised, of which three discontinued treatment early leaving 66 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in both groups (MADRS reduction in sham = 7.0 [95%CI 5.0-8.9]; and active = 5.2 [95%CI 3.2-7.3]). However, there were no differences between active and sham groups in the reduction of depressive symptoms, or the number of participants meeting response (sham = 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema, paraesthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active tRNS group. Neuroplasticity, neuropsychological and acute cognitive effects were comparable between groups.
Conclusion Our results do not support the use of tRNS with the current stimulation parameters as a therapeutic intervention for the treatment of depression.
Clinical trial registration at clinicaltrials.gov/NCT01792414.
Significance Statement This is the first randomized sham-controlled clinical trial of a four-week course of transcranial random noise stimulation (tRNS) for the treatment of depression. tRNS is a relatively novel form of non-invasive electrical stimulation that uses mild, randomly fluctuating currents to constrain homeostatic mechanisms and increase brain excitability. We investigated effects across multiple validated mood outcomes and comprehensively assessed cognitive, neurophysiological, and physical side effects to examine the safety of tRNS. We found no differences between active and sham conditions for all mood outcomes, and are thus unable to lend support for tRNS as an effective treatment for depression. We found tRNS to be well-tolerated with no adverse acute cognitive, neuropsychological or severe phyisical side effects, suggesting a course of 20 repeated sessions can be delivered safely.
Competing Interest Statement
CL has served on a Janssen Advisory Board for Janssen and received an honorarium from Mecta for teaching at an international electroconvulsive therapy (ECT) course. The remaining authors have no conflicts of interest to declare.
Clinical Trial
Clinical Trial ID from www.clinicaltrials.gov: NCT01792414
Funding Statement
NHMRC project grant: APP1051423
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Funding NHMRC project grant APP1051423
Data Availability
Participant consent was not obtained to make data publically available. However, syntax and output from statistical analyses can be found at: https://github.com/snikolin/tRNSdepressionRCT
